{
    "clinical_study": {
        "@rank": "95764", 
        "arm_group": {
            "arm_group_label": "Patients with T2DM"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to monitor the safety profile of Trajenta Duo in\n      Korean patients with type 2 diabetes mellitus (T2DM) in a routine clinical setting."
        }, 
        "brief_title": "A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study Design:\n\n      PMS Observational study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Potential subjets must meet all of the following inclusion criteria to enter this trial:\n\n          1. No previous exposure to Trajenta, Trajenta Duo\n\n          2. Should have been started on Trajenta Duo in accordance with the approved label in\n             Korea\n\n          3. No current participation in clinical trials\n\n          4. No metformin is inappropriate due to contraindications\n\n          5. Must sign on the data release consent form\n\n        Exclusion criteria:\n\n        Individuals with any of the following characteristics will not be able to enter this\n        study:\n\n          1. Previous exposure to Trajenta, Trajenta Duo\n\n          2. Current participation in clinical trials\n\n          3. Patients for whom metformin is inappropriate due to contraindications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Korean patients with T2DM"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903356", 
            "org_study_id": "1288.22"
        }, 
        "intervention": {
            "arm_group_label": "Patients with T2DM", 
            "description": "Linagliptin and Metformin", 
            "intervention_name": "Trajenta duo", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 9"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 3"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Choongnam", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 10"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 4"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonggi", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 5"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeongsangnam-do", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 2"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 7"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 8"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 1"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 11"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 6"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta Duo\u00ae (Linagliptin/Metformin HCl, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, b.i.d) in Korean Patients With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety (MFDS)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events in patients who take at least one dose of Trajenta Duo", 
            "safety_issue": "Yes", 
            "time_frame": "up to 26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903356"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in Glucosylated Hemoglobin (HbA1c) after 24 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 26 weeks"
            }, 
            {
                "measure": "Occurence of treat to target effectiveness response, that is an Glucosylated Hemoglobin (HbA1c) under treatment of < 6.5% after 24 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 26 weeks"
            }, 
            {
                "measure": "Occurence of relative effectiveness response (HbA1c lowering by at least 0.5% after 24 weeks)", 
                "safety_issue": "No", 
                "time_frame": "up to 26 weeks"
            }, 
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG) after 24 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 26 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}